Aptar Declares Quarterly Dividend and Announces 2025 Annual Meeting Details
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that the Board declared a quarterly cash dividend of $0.45 per share. The payment date is February 26, 2025, to stockholders of record as of February 5, 2025.
Aptar Named One of America’s Most Responsible Companies by Newsweek for the Sixth Consecutive Year
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of America’s Most Responsible Companies 2025 by Newsweek for the sixth consecutive year. Aptar is ranked number 71 out of 600 U.S. companies.
Aptar Announces 2025 Quarterly Conference Call Dates
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases.
Aptar to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced their participation at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025.
Aptar Named Among Top 50 of the ‘World’s Top Companies for Women 2024’ by Forbes
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named a World’s Top Companies for Women 2024 by Forbes for the fourth consecutive year (formerly World’s Top Female Friendly Companies). Aptar is ranked 41 out of the 400 companies included on the list by Forbes and their partner Statista. For this ranking companies were evaluated in three categories including employer brand, public opinion and leadership.
Aptar Reports Third Quarter 2024 Results
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year.
Aptar Awarded Federal Government Contract to Advance Novel Sterilization Technology for Medical Devices
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that it was awarded a contract from the U.S. Federal Government to advance development of its ActivShield™ technology. This innovative solution sterilizes medical devices and instruments without the need for a power source, making it a versatile solution for numerous environments, including rural areas, military settings and healthcare facilities with limited or no current sterilization capability.
Aptar Announces New $500 Million Share Repurchase Authorization and Declares Quarterly Dividend
The Board of Directors of AptarGroup, Inc. (
NYSEATR) authorized the repurchase of up to $500 million of the Company’s common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also declared a quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024.
Aptar’s N-Sorb Nitrosamine Mitigation Solution Accepted to US FDA’s Emerging Technology Program
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that its N-Sorb nitrosamine mitigation solution has been accepted into the U.S. Food & Drug Administration’s (FDA) Emerging Technology Program (ETP), which helps promote the adoption of innovative approaches to pharmaceutical product design and manufacturing.
Aptar’s Nasal Unidose System to Deliver neffy® (epinephrine nasal spray), the First and Only FDA-Approved Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Unidose Liquid System (Unidose) is the delivery system approved with neffy® (epinephrine nasal spray), the first and only needle-free treatment approved by the U.S. FDA for the emergency treatment of patients with allergic reactions (Type I), including anaphylaxis. This marks the first regulatory approval worldwide for nasally-delivered epinephrine.
Daniel Ackerman Named Aptar’s Chief Accounting Officer
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Daniel Ackerman has been named Chief Accounting Officer, effective August 1, 2024.
Aptar CFO, Robert (Bob) Kuhn, Has Decided to Step Down After 37 Years with the Company
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year.
Aptar Reports Second Quarter 2024 Results
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported solid second quarter results driven by continued growth of the company’s proprietary drug delivery systems and margin improvement. Reported sales increased by 2% and core sales, excluding currency and acquisition effects, increased by 3%. Aptar reported net income of $90 million for the quarter, a 9% increase from the prior year.
Aptar Increases Quarterly Dividend by Nearly 10% Due to Continued Strong Performance
AptarGroup, Inc. (
NYSEATR), a global leader in drug delivery, consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share, an almost 10% increase from the previous dividend amount, bringing the new annualized dividend to $1.80 per share. The payment date is August 15, 2024, to stockholders of record as of July 25, 2024.
Aptar Named One of the World’s Most Sustainable Companies 2024 by TIME
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of the World’s Most Sustainable Companies 2024 by TIME. Aptar is ranked 194 out of top 500 global companies evaluated by TIME and its partner Statista.
Aptar Named One of America’s Climate Leaders by USA Today
AptarGroup, Inc. (
NYSEATR), a global leader in drug delivery, consumer product dispensing and protection technologies was named one of America’s Climate Leaders 2024 by USA Today.
Aptar Releases 2023 Corporate Sustainability / ESG Report
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today released its 2023 Corporate Sustainability / Environment, Social and Governance (ESG) Report entitled Progress Takes Shape. Aptar’s report highlights key milestones of its global sustainability strategy across the company’s global operations focused on three key pillars:
Aptar Receives Platinum Rating from EcoVadis for the Fourth Consecutive Year
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies has achieved the Platinum level rating in recognition of its sustainability efforts from EcoVadis for the fourth consecutive year. The Platinum rating places Aptar among the top 1% of the more than 125,000 companies rated by EcoVadis across all industries.
Aptar Reports First Quarter 2024 Results
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong first quarter results driven by continued growth of the company’s proprietary drug delivery systems, increased injectables sales and an improving picture for consumer dispensing technologies in North America. Reported sales increased by 6% and core sales, excluding currency and acquisition effects, increased by 5%. Aptar reported net income of $83 million for the quarter, a 52% increase over the prior year. Reported earnings per share increased 50% to $1.23 and adjusted earnings per share increased 31% to $1.26.
Aptar Declares Quarterly Dividend
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.41 per share. The payment date is May 16, 2024, to stockholders of record as of April 25, 2024.
Aptar Named a CDP Supplier Engagement Leader for the Fourth Consecutive Year
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, was named to the CDP Supplier Engagement Leaderboard, for the fourth consecutive year. Aptar is among over 450 companies that have made it onto CDP’s most recent Supplier Engagement Leaderboard based on its 2023 CDP disclosure and was cited for its contributions to emissions reductions throughout the value chain.
Aptar Named One of Barron’s 100 Most Sustainable U.S. Companies for the Sixth Consecutive Year
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the sixth consecutive year and is ranked number 29 out of 100 companies for 2024.
Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
Aptar Digital Health, part of AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has entered into an enterprise agreement with Biogen Inc. (Nasdaq: BIIB) to operate and develop digital health solutions for neurological and rare diseases. As part of the agreement, Biogen will transfer ownership of select digital health solutions to Aptar Digital Health (Aptar).
Aptar Reports Fourth Quarter and Annual 2023 Results
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter operational results driven by double-digit growth of the company’s proprietary drug delivery systems and strong growth for fragrance dispensing technologies. Reported sales increased by 5% and core sales, excluding currency and acquisition effects, increased by 2%. Aptar reported net income of $62 million for the quarter, a 6% increase over the prior year.
Aptar Named One of America’s Most Responsible Companies by Newsweek for the Fifth Consecutive Year
AptarGroup, Inc. (
NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of America’s Most Responsible Companies 2024 by Newsweek for the fifth consecutive year. Aptar is ranked number 29 out of 600 U.S. companies and is ranked first in its industry category.
